The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program ...

twice-yearly lenacapavir has demonstrated its potential as an important new tool to help prevent HIV infections,” said Gilead ...

which could significantly expand the number of patients who could be treated with our current supply of remdesivir," Gilead Chief Medical Officer Merdad Parsey said in a release. "This is ...

Gilead Sciences, Inc. (NASDAQ:GILD) Chief Medical Officer Merdad Parsey has recently engaged in significant trading activity, according to the latest filings with the Securities and Exchange ...

“Our data at WCLC will add to the expanding evidence for the potential of Trodelvy in lung cancer and reinforce our confidence in our broader lung cancer strategy,” said Merdad ...

Gilead Sciences, Inc. (NASDAQ:GILD) Chief Medical Officer Merdad Parsey has recently engaged in significant trading activity, according to the latest filings with the Securities and Exchange ...

Multiple concurrent studies are helping inform whether remdesivir is a safe and effective treatment for COVID-19 and how to best utilize the drug,” said chief medical officer Merdad Parsey.

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $81.44 which represents a slight increase of $2.27 or 2.87% from the prior close of $79.17. The stock opened at $79.17 and ...

including those that may be susceptible to higher rates of COVID-19 infection, as well as others that are particularly vulnerable, including children and pregnant and postpartum women," Parsey added.

came in remarks by Gilead's chief medical officer Merdad Parsey in the company's third-quarter results call. Parsey said the FDA has concerns about the "manufacture and delivery" of Hepcludex but ...

Gilead Sciences' chief medical officer, Merdad Parsey, will leave the company in early 2025, becoming the latest in a series of high-profile departures involving senior R&D figures at top drugmakers.